Updates

XP Power

February 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

XPP’s Q4 update matched Q3 at £60m sales. Within the mix, the Industrial Technology and Healthcare sectors grew sequentially. Order intake from the Semiconductor Manufacturing Equipment sector did not match a particularly strong Q3 when sales had doubled, although conditions are generally improving. Order intake overall for the quarter was £44.9m, versus £48.8m in Q3 so XPP’s book to bill was 0.75x, down from 0.8x in Q3 when it marked the first quarter of growth since late 2022. EPS forecast for the year ended 31 December is 43.7p with 78.8p this year. Buy. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

H&T

Renew - Slower start to CP7 but water outperforming

XP Power - £41m placing to reduce debts (April 2025)

XP Power - Semiconductor side recover (November 2024)

XP Power (September 2024)

XP Power - Unmarried but not unloved (July 2024)

XP Power - Denver rival launches bid at 1950p (June 2024)

XP Power - 35:65% H1:H2 weighting to profits this year (May 2024)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X